Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Curis, Aurigene Join For Oncology Drugs
by Michael McCoy
January 26, 2015
| A version of this story appeared in
Volume 93, Issue 4
Curis has signed an agreement giving it the right to license multiple small-molecule oncology drug candidates discovered by India’s Aurigene Discovery Technologies. The first two compounds up for license are an antagonist of PD-L1 in the immuno-oncology field and an inhibitor of IRAK4 in the precision oncology field. Curis has issued to Aurigene shares of Curis stock valued at roughly $25 million and will make up to $42.5 million in milestone payments for each of the two programs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X